2018
Gastrointestinal and Extra-Intestinal Manifestations of IgG4–Related Disease
Miyabe K, Zen Y, Cornell LD, Rajagopalan G, Chowdhary VR, Roberts LR, Chari ST. Gastrointestinal and Extra-Intestinal Manifestations of IgG4–Related Disease. Gastroenterology 2018, 155: 990-1003.e1. PMID: 30012334, DOI: 10.1053/j.gastro.2018.06.082.Peer-Reviewed Original ResearchConceptsIgG4-RDPlasma cellsExtra-intestinal manifestationsHuman IgG4-RDSimilar immune reactionsRelapsing-remitting courseDense lymphoplasmacytic infiltrateTiters of autoantibodiesMulti-organ diseasePermanent organ damageObliterative phlebitisStoriform fibrosisAutoimmune etiologyMetachronous lesionsPrimary therapyExcellent prognosisLymph nodesLymphoplasmacytic infiltrateSerum levelsOrgan damageSerum IgG4Bile ductAutoimmune diseasesTypical presentationInflammatory response
2017
Randomized Clinical Trial of a Combination of an Inhaled Corticosteroid and Beta Agonist in Patients at Risk of Developing the Acute Respiratory Distress Syndrome*
Festic E, Carr G, Cartin-Ceba R, Hinds R, Banner-Goodspeed V, Bansal V, Asuni A, Talmor D, Rajagopalan G, Frank R, Gajic O, Matthay M, Levitt J. Randomized Clinical Trial of a Combination of an Inhaled Corticosteroid and Beta Agonist in Patients at Risk of Developing the Acute Respiratory Distress Syndrome*. Critical Care Medicine 2017, 45: 798-805. PMID: 28240689, PMCID: PMC5392150, DOI: 10.1097/ccm.0000000000002284.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdministration, InhalationAdrenal Cortex HormonesAdrenergic beta-AgonistsAgedAged, 80 and overBiomarkersBudesonide, Formoterol Fumarate Drug CombinationDouble-Blind MethodDrug Therapy, CombinationFemaleHumansHypoxiaMaleMiddle AgedOxygenPatient AcuityRespiration, ArtificialRespiratory Distress SyndromeRisk FactorsUnited StatesConceptsAcute respiratory distress syndromeRespiratory distress syndromeBudesonide/formoterolDistress syndromeBeta agonistsMore patientsMechanical ventilationClinical trialsEarly treatmentFirst study drugAlveolar fluid clearanceEffective pharmacologic treatmentRandomized clinical trialsPlacebo bidCategorical changePlacebo groupStudy drugAdult patientsLung inflammationLung injuryPharmacologic treatmentPrimary outcomeMedian timeEmergency departmentImproved oxygenation